ClinicalTrials.Veeva
Menu

Find clinical trials for Pancreatic Cancer in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Adenocarcinoma
Cancer
Non-Small-Cell Lung Carcinoma
Colorectal Cancer
Carcinoma
Lung Cancer
Ovarian Cancer

Pancreatic Cancer trials near Paris, Île-de-France, FRA:

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer...

Active, not recruiting
Metastatic Pancreatic Adenocarcinoma
Metastatic Pancreatic Cancer
Drug: nab-paclitaxel
Drug: gemcitabine

Phase 2

Astellas
Astellas

Villejuif, Villejuif Cedex, France and 135 other locations

assessed by estimating Objective response rate (ORR) according to Response Evaluation Criteria version 1.1 (RECIST 1.1) in patients with pancreatic...

Enrolling
Pancreas Neoplasms
Drug: Vitamin D3 (Cholecalciferol)
Drug: Dostarlimab

Phase 2

Hopital Foch

Paris, France and 4 other locations

phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety pr...

Enrolling
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Drug: AMG 193
Drug: Gemcitabine

Phase 1

Amgen
Amgen

Villejuif, France and 76 other locations

Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic du...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Biological: CD40 agonist mitazalimab in combination with chemotherapy

Phase 1, Phase 2

Alligator Bioscience

Paris, France and 13 other locations

Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC);* PROCEADE PanTumor: A Phase 1b/2, Multicenter, O ...

Enrolling
Gastric Cancer
Non-Small Cell Lung Cancer (NSCLC)
Drug: M9140

Phase 1, Phase 2

Merck KGaA (EMD Serono)
Merck KGaA (EMD Serono)

Paris, France and 36 other locations

to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor...

Active, not recruiting
Non-small Cell Lung Cancer
Colorectal Neoplasms
Drug: PF-08046049

Phase 1

Seagen, a wholly owned subsidiary of Pfizer

Villejuif, Cedex, France and 29 other locations

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Enrolling
PDAC - Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer
Drug: 5-fluorouracil
Drug: leucovorin

Phase 3

Revolution Medicines
Revolution Medicines

Villejuif, France and 59 other locations

concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors...

Enrolling
Bladder Cancer
Solid Tumor, Adult
Drug: Association atezolizumab + BDB001+ RT
Drug: Association atezolizumab + BDB001 + RT

Phase 2

Institut Bergonié

Paris, France and 10 other locations

to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors...

Active, not recruiting
Pancreatic Cancer Harboring NRG1 Fusion
NSCLC Harboring NRG1 Fusion
Drug: zenocutuzumab (MCLA-128)

Phase 2

Partner Therapeutics

Paris, France and 63 other locations

This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors...

Active, not recruiting
Exocrine Pancreatic Cancer
Colorectal Neoplasms
Drug: cisplatin
Drug: carboplatin

Phase 2

Seagen, a wholly owned subsidiary of Pfizer

Villejuif, France and 149 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems